Counseling for Harm Reduction and Retention in Medication-assisted Treatment - Cherokee Nation

The goal of this randomized clinical trial is to test the efficacy of a program meant to enhance Counseling for Harm Reduction and Retention in MAT in Cherokee Nation (CHaRRM-CN). The main questions it aims to answer are whether CHaRRM-CN: improves retention of patients in MAT, decreases substance-related harm and illicit opioid use, and increases cultural connectedness. After providing written, informed consent, participants will attend a baseline assessement and will then be randomized to either the CHaRRM-CN or treatment as usual group. For 6 months after randomization, participants will be exposed to CHaRRM-CN or treatment as usual. During that time, participants will also attend the 1-month, 3-month and 6-month follow-ups to track their progress through the programs. After the 6 months of either treatment condition, investigators will compare the groups to see if they differ on retention, substance-use outcomes and Native enculturation.

NCT Number	NCT05733442
Lead Sponsor	Washington State University Collaborators: University of Washington, Cherokee Nation Health Services, National Institute on Drug Abuse (NIDA)
Conditions	Opioid Use Disorder
Enrollment	136 participants
Start Date	2023-01-17
Primary Completion	2026-05-15 (estimated)
Study Completion	2026-07-31 (estimated)
Updated on ClinicalTrials.gov	2026-05-05